Clinical-TrialsSeveral studies are currently underway to help increase our understanding of the causes of diabetes and its complications, and to develop better strategies to prevent and manage its complications. Our Diabetes & Endocrinology Clinical Research Unit (DECRU) offers our patients and other volunteers the opportunity to participate in state-of-the-art phase I, II, III, and IV clinical trials with investigational medications for the treatment of diabetes and related metabolic disorders.

For further information about our DECRU and our clinical trials please contact:
Kentress Davison
Clinical Trial Administrator , Diabetes & Endocrine Clinical Research Unit
FOT 702
510 20th Street South
Birmingham, AL 35294
Phone 205-934-4112; Fax 205-934-4379

Studies Open for Enrollment

  • Changes in Bone Turnover with Increased Incretin Hormone Exposure
  • Changes in Bone Turnover with Exposure to a GLP-1 Receptor Agonist
  • Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes
  • A randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrierĀ® Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Metformin and/or SUAnti- Diabetes Agents
  • A randomized Clinical Trial of Subcutaneous Analog Basal Bolus Therapy Versus Sliding Scale Human Regular Insulin in the Hospital Management of Hyperglycemia in Non-Critically Ill Patients without Known History of Diabetes
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination with Metformin compared to Therapy with Placebo added to Dapagliflozin in combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Dapagliflozin
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Metformin compared to Therapy with Placebo added to Saxagliptin in Combination with Metformin in Subjects with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin and Saxagliptin
  • A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults